본문바로가기
Q
U
I
C
K

PR

SK bioscience company news updates

Press releases

SK bioscience Is Officially Established

2018. 07. 02

- SK chemicals spins off its vaccine business into SK bioscience

SK bioscience was officially launched on July 1, 2018.

SK chemicals announced that the company has spun off its vaccine business to set up SK bioscience. The newly-formed company will be a wholly-owned subsidiary of SK chemicals, which will hold 100% of the shares issued by SK bioscience.

Following the spinoff, SK Chemicals will enhance its expertise on environmentally-friendly materials and synthetic drugs while SK bioscience will focus on its vaccine business. The new vaccine subsidiary will also focus on facilitating foreign investments and maximize management efficiency to improve its shareholder value.

Jaeyong Ahn, General Manager of SK chemicals’ Vaccine Business Division, was appointed as CEO of SK bioscience.

Mr. Ahn said "SK bioscience´s innovative R&D technology and manufacturing facilities will become the cornerstones for our success. Based on our core strengths, we plan to establish our identity and reinforce expertise and efficiency to become a competitive global vaccine maker.”

Based on its next-generation vaccines that were developed with global partners and globally recognized vaccine plant, the new company plans to establish a leading position in the domestic market as well as make inroads into overseas markets.

SK bioscience has developed the Korea’s only cell culture-based influenza vaccine ´SKYCellflu®´and ´SKYCellflu Quadrivalent´. The vaccines have exceeded 14 million doses in cumulative sales in Korea within three years after launching. The company is also planning to bid for international contracts through WHO’s Pre-Qualification certification. Moreover, the vaccine maker signed a $155 million contract to transfer influenza vaccine production technologies to Sanofi in February, 2018.


SK bioscience’s ´SKYZoster®´, the world second vaccine for herpes zoster to be commercialized globally, achieved a 50 percent market share in Korea in the first year of its launching and made inroads into developing countries. With its varicella vaccine, ´SKYVaricella®´, for which sales approval was obtained last month, the company is expected to concurrently supply the vaccine to the domestic market and bid for international contracts.


SK bioscience will continuously forge partnerships with public and private institutions around the globe, such as Sanofi Pasteur, the Bill & Melinda Gates Foundation, International Vaccine Institute and PATH, and attract strategic investors to accelerate expansion into overseas markets.

The company has reliable manufacturing infrastructure to produce and supply all its vaccines. called, L HOUSE. The plant is capable of producing most of vaccines developed in Korea through cutting-edge technologies, including cell culture, bacterial culture, genetic recombination and protein conjugate vaccines.